ACADIA Pharmaceuticals Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?

ACADIA vs. Mesoblast: A Decade of SG&A Cost Management

__timestampACADIA Pharmaceuticals Inc.Mesoblast Limited
Wednesday, January 1, 20143274800054170000
Thursday, January 1, 20159080400065378000
Friday, January 1, 201618645600052263000
Sunday, January 1, 201725506200035072000
Monday, January 1, 201826575800027415000
Tuesday, January 1, 201932563800036983000
Wednesday, January 1, 202038866100050918000
Friday, January 1, 202139602800063586000
Saturday, January 1, 202236909000057967000
Sunday, January 1, 202340246600053107000
Monday, January 1, 202423626000
Loading chart...

Unlocking the unknown

Who Manages SG&A Costs Better: ACADIA Pharmaceuticals Inc. or Mesoblast Limited?

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, ACADIA Pharmaceuticals Inc. and Mesoblast Limited have shown contrasting trends in their SG&A costs. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. In contrast, Mesoblast's expenses remained relatively stable, with a modest increase of about 2% over the same period. This stark difference highlights ACADIA's aggressive expansion strategy, while Mesoblast appears to focus on cost containment. Notably, ACADIA's expenses in 2023 were nearly seven times higher than Mesoblast's, raising questions about the sustainability of such growth. As we look to the future, the missing data for 2024 suggests uncertainty, but the trends so far provide valuable insights into each company's financial strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025